Biocon Limited
Biocon Limited (BIOCON.BO) Stock Competitors & Peer Comparison
See (BIOCON.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIOCON.BO | ₹362.80 | +3.49% | 459.2B | 74.44 | ₹4.86 | +0.14% |
| BIOCON.NS | ₹362.80 | +3.70% | 459.4B | 74.33 | ₹4.87 | +0.14% |
| ANTHEM.NS | ₹774.30 | +4.64% | 432.4B | 89.71 | ₹8.58 | N/A |
| PPLPHARMA.NS | ₹164.47 | -0.60% | 223.4B | -136.11 | -₹1.24 | +0.08% |
| ONESOURCE.NS | ₹1,763.00 | -3.36% | 209.9B | 1034.69 | ₹1.77 | N/A |
| SYNGENE.NS | ₹440.25 | +4.52% | 175.9B | 50.11 | ₹8.74 | +0.29% |
| SYNGENE.BO | ₹440.00 | +4.60% | 175.9B | 50.10 | ₹8.74 | +0.29% |
| JUBLINGREA.NS | ₹720.30 | -2.47% | 115.9B | 43.80 | ₹16.77 | +0.68% |
| CONCORDBIO.NS | ₹1,072.00 | +5.49% | 110.7B | 35.54 | ₹29.77 | +1.01% |
| CONCORDBIO.BO | ₹1,071.05 | +5.33% | 110.6B | 35.53 | ₹29.76 | +1.01% |
Stock Comparison
BIOCON.BO vs BIOCON.NS Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, BIOCON.NS has a market cap of 459.4B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while BIOCON.NS trades at ₹362.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas BIOCON.NS's P/E ratio is 74.33. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to BIOCON.NS's ROE of +0.02%. Regarding short-term risk, BIOCON.BO is more volatile compared to BIOCON.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BIOCON.BO.Check BIOCON.NS's competition here
BIOCON.BO vs ANTHEM.NS Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, ANTHEM.NS has a market cap of 432.4B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while ANTHEM.NS trades at ₹774.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas ANTHEM.NS's P/E ratio is 89.71. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to ANTHEM.NS's ROE of +0.19%. Regarding short-term risk, BIOCON.BO is less volatile compared to ANTHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check ANTHEM.NS's competition here
BIOCON.BO vs PPLPHARMA.NS Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, PPLPHARMA.NS has a market cap of 223.4B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while PPLPHARMA.NS trades at ₹164.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas PPLPHARMA.NS's P/E ratio is -136.11. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to PPLPHARMA.NS's ROE of -0.02%. Regarding short-term risk, BIOCON.BO is less volatile compared to PPLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check PPLPHARMA.NS's competition here
BIOCON.BO vs ONESOURCE.NS Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, ONESOURCE.NS has a market cap of 209.9B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while ONESOURCE.NS trades at ₹1,763.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas ONESOURCE.NS's P/E ratio is 1034.69. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to ONESOURCE.NS's ROE of +0.00%. Regarding short-term risk, BIOCON.BO is less volatile compared to ONESOURCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check ONESOURCE.NS's competition here
BIOCON.BO vs SYNGENE.NS Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, SYNGENE.NS has a market cap of 175.9B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while SYNGENE.NS trades at ₹440.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas SYNGENE.NS's P/E ratio is 50.11. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to SYNGENE.NS's ROE of +0.07%. Regarding short-term risk, BIOCON.BO is less volatile compared to SYNGENE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check SYNGENE.NS's competition here
BIOCON.BO vs SYNGENE.BO Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, SYNGENE.BO has a market cap of 175.9B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while SYNGENE.BO trades at ₹440.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas SYNGENE.BO's P/E ratio is 50.10. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to SYNGENE.BO's ROE of +0.07%. Regarding short-term risk, BIOCON.BO is less volatile compared to SYNGENE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check SYNGENE.BO's competition here
BIOCON.BO vs JUBLINGREA.NS Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, JUBLINGREA.NS has a market cap of 115.9B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while JUBLINGREA.NS trades at ₹720.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas JUBLINGREA.NS's P/E ratio is 43.80. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to JUBLINGREA.NS's ROE of +0.09%. Regarding short-term risk, BIOCON.BO is less volatile compared to JUBLINGREA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check JUBLINGREA.NS's competition here
BIOCON.BO vs CONCORDBIO.NS Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, CONCORDBIO.NS has a market cap of 110.7B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while CONCORDBIO.NS trades at ₹1,072.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas CONCORDBIO.NS's P/E ratio is 35.54. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to CONCORDBIO.NS's ROE of +0.18%. Regarding short-term risk, BIOCON.BO is less volatile compared to CONCORDBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check CONCORDBIO.NS's competition here
BIOCON.BO vs CONCORDBIO.BO Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, CONCORDBIO.BO has a market cap of 110.6B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while CONCORDBIO.BO trades at ₹1,071.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas CONCORDBIO.BO's P/E ratio is 35.53. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to CONCORDBIO.BO's ROE of +0.18%. Regarding short-term risk, BIOCON.BO is less volatile compared to CONCORDBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check CONCORDBIO.BO's competition here
BIOCON.BO vs BLUEJET.BO Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, BLUEJET.BO has a market cap of 77B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while BLUEJET.BO trades at ₹443.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas BLUEJET.BO's P/E ratio is 26.26. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to BLUEJET.BO's ROE of +0.26%. Regarding short-term risk, BIOCON.BO is less volatile compared to BLUEJET.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check BLUEJET.BO's competition here
BIOCON.BO vs BLUEJET.NS Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, BLUEJET.NS has a market cap of 77B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while BLUEJET.NS trades at ₹443.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas BLUEJET.NS's P/E ratio is 26.25. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to BLUEJET.NS's ROE of +0.26%. Regarding short-term risk, BIOCON.BO is less volatile compared to BLUEJET.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check BLUEJET.NS's competition here
BIOCON.BO vs SUPRIYA.BO Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, SUPRIYA.BO has a market cap of 56.7B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while SUPRIYA.BO trades at ₹704.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas SUPRIYA.BO's P/E ratio is 30.56. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to SUPRIYA.BO's ROE of +0.19%. Regarding short-term risk, BIOCON.BO is less volatile compared to SUPRIYA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check SUPRIYA.BO's competition here
BIOCON.BO vs SUPRIYA.NS Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, SUPRIYA.NS has a market cap of 56.7B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while SUPRIYA.NS trades at ₹704.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas SUPRIYA.NS's P/E ratio is 30.61. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to SUPRIYA.NS's ROE of +0.19%. Regarding short-term risk, BIOCON.BO is less volatile compared to SUPRIYA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check SUPRIYA.NS's competition here
BIOCON.BO vs ZOTA.NS Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, ZOTA.NS has a market cap of 40B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while ZOTA.NS trades at ₹1,303.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas ZOTA.NS's P/E ratio is -54.82. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to ZOTA.NS's ROE of -0.31%. Regarding short-term risk, BIOCON.BO is less volatile compared to ZOTA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check ZOTA.NS's competition here
BIOCON.BO vs DCAL.BO Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, DCAL.BO has a market cap of 27.4B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while DCAL.BO trades at ₹184.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas DCAL.BO's P/E ratio is 23.09. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to DCAL.BO's ROE of +0.02%. Regarding short-term risk, BIOCON.BO is less volatile compared to DCAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check DCAL.BO's competition here
BIOCON.BO vs DCAL.NS Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, DCAL.NS has a market cap of 27.4B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while DCAL.NS trades at ₹184.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas DCAL.NS's P/E ratio is 23.06. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to DCAL.NS's ROE of +0.02%. Regarding short-term risk, BIOCON.BO is less volatile compared to DCAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check DCAL.NS's competition here
BIOCON.BO vs PANACEABIO.BO Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, PANACEABIO.BO has a market cap of 22.6B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while PANACEABIO.BO trades at ₹377.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas PANACEABIO.BO's P/E ratio is -286.32. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to PANACEABIO.BO's ROE of -0.01%. Regarding short-term risk, BIOCON.BO is less volatile compared to PANACEABIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check PANACEABIO.BO's competition here
BIOCON.BO vs PANACEABIO.NS Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, PANACEABIO.NS has a market cap of 22.6B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while PANACEABIO.NS trades at ₹377.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas PANACEABIO.NS's P/E ratio is -285.93. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to PANACEABIO.NS's ROE of -0.01%. Regarding short-term risk, BIOCON.BO is less volatile compared to PANACEABIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check PANACEABIO.NS's competition here
BIOCON.BO vs TITANBIO.BO Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, TITANBIO.BO has a market cap of 19.4B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while TITANBIO.BO trades at ₹452.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas TITANBIO.BO's P/E ratio is 71.40. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to TITANBIO.BO's ROE of +0.18%. Regarding short-term risk, BIOCON.BO is less volatile compared to TITANBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check TITANBIO.BO's competition here
BIOCON.BO vs 3BBLACKBIO.BO Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, 3BBLACKBIO.BO has a market cap of 11.1B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while 3BBLACKBIO.BO trades at ₹1,309.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas 3BBLACKBIO.BO's P/E ratio is 19.49. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to 3BBLACKBIO.BO's ROE of N/A. Regarding short-term risk, BIOCON.BO is more volatile compared to 3BBLACKBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOCON.BO.Check 3BBLACKBIO.BO's competition here
BIOCON.BO vs FERMENTA.BO Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, FERMENTA.BO has a market cap of 9.2B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while FERMENTA.BO trades at ₹312.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas FERMENTA.BO's P/E ratio is 10.61. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to FERMENTA.BO's ROE of +0.25%. Regarding short-term risk, BIOCON.BO is less volatile compared to FERMENTA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check FERMENTA.BO's competition here
BIOCON.BO vs TAKE.NS Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, TAKE.NS has a market cap of 6.7B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while TAKE.NS trades at ₹44.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas TAKE.NS's P/E ratio is -453.40. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to TAKE.NS's ROE of +0.12%. Regarding short-term risk, BIOCON.BO is more volatile compared to TAKE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BIOCON.BO.Check TAKE.NS's competition here
BIOCON.BO vs TAKE.BO Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, TAKE.BO has a market cap of 6.7B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while TAKE.BO trades at ₹44.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas TAKE.BO's P/E ratio is -451.20. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to TAKE.BO's ROE of +0.12%. Regarding short-term risk, BIOCON.BO is more volatile compared to TAKE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOCON.BO.Check TAKE.BO's competition here
BIOCON.BO vs KILPEST.BO Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, KILPEST.BO has a market cap of 6.3B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while KILPEST.BO trades at ₹808.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas KILPEST.BO's P/E ratio is 18.32. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to KILPEST.BO's ROE of N/A. Regarding short-term risk, BIOCON.BO is less volatile compared to KILPEST.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check KILPEST.BO's competition here
BIOCON.BO vs SMSLIFE.BO Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, SMSLIFE.BO has a market cap of 4.3B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while SMSLIFE.BO trades at ₹1,440.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas SMSLIFE.BO's P/E ratio is 22.81. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to SMSLIFE.BO's ROE of +0.10%. Regarding short-term risk, BIOCON.BO is less volatile compared to SMSLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check SMSLIFE.BO's competition here
BIOCON.BO vs HALEOSLABS.BO Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, HALEOSLABS.BO has a market cap of 4.1B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while HALEOSLABS.BO trades at ₹1,428.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas HALEOSLABS.BO's P/E ratio is 20.73. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to HALEOSLABS.BO's ROE of +0.09%. Regarding short-term risk, BIOCON.BO is less volatile compared to HALEOSLABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check HALEOSLABS.BO's competition here
BIOCON.BO vs HALEOSLABS.NS Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, HALEOSLABS.NS has a market cap of 4.1B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while HALEOSLABS.NS trades at ₹1,438.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas HALEOSLABS.NS's P/E ratio is 20.73. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to HALEOSLABS.NS's ROE of +0.09%. Regarding short-term risk, BIOCON.BO is less volatile compared to HALEOSLABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check HALEOSLABS.NS's competition here
BIOCON.BO vs SMSLIFE.NS Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, SMSLIFE.NS has a market cap of 3.9B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while SMSLIFE.NS trades at ₹1,299.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas SMSLIFE.NS's P/E ratio is 21.01. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to SMSLIFE.NS's ROE of +0.10%. Regarding short-term risk, BIOCON.BO is more volatile compared to SMSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BIOCON.BO.Check SMSLIFE.NS's competition here
BIOCON.BO vs LYKALABS.BO Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, LYKALABS.BO has a market cap of 2.1B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while LYKALABS.BO trades at ₹60.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas LYKALABS.BO's P/E ratio is 100.00. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to LYKALABS.BO's ROE of -0.01%. Regarding short-term risk, BIOCON.BO is less volatile compared to LYKALABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check LYKALABS.BO's competition here
BIOCON.BO vs LYKALABS.NS Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, LYKALABS.NS has a market cap of 2.1B. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while LYKALABS.NS trades at ₹59.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas LYKALABS.NS's P/E ratio is -343.82. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to LYKALABS.NS's ROE of -0.01%. Regarding short-term risk, BIOCON.BO is less volatile compared to LYKALABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check LYKALABS.NS's competition here
BIOCON.BO vs ALFAVIO.BO Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, ALFAVIO.BO has a market cap of 490.5M. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while ALFAVIO.BO trades at ₹15.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas ALFAVIO.BO's P/E ratio is -518.67. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to ALFAVIO.BO's ROE of -0.00%. Regarding short-term risk, BIOCON.BO is more volatile compared to ALFAVIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOCON.BO.Check ALFAVIO.BO's competition here
BIOCON.BO vs SAMSRITA.BO Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, SAMSRITA.BO has a market cap of 253.8M. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while SAMSRITA.BO trades at ₹17.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas SAMSRITA.BO's P/E ratio is -4.30. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to SAMSRITA.BO's ROE of -0.61%. Regarding short-term risk, BIOCON.BO is more volatile compared to SAMSRITA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOCON.BO.Check SAMSRITA.BO's competition here
BIOCON.BO vs TRABI.BO Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, TRABI.BO has a market cap of 217.5M. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while TRABI.BO trades at ₹2.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas TRABI.BO's P/E ratio is -11.48. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to TRABI.BO's ROE of -0.19%. Regarding short-term risk, BIOCON.BO is less volatile compared to TRABI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check TRABI.BO's competition here
BIOCON.BO vs STARSOURCE.BO Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, STARSOURCE.BO has a market cap of 169.4M. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while STARSOURCE.BO trades at ₹118.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas STARSOURCE.BO's P/E ratio is -1.40. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to STARSOURCE.BO's ROE of -0.93%. Regarding short-term risk, BIOCON.BO is less volatile compared to STARSOURCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check STARSOURCE.BO's competition here
BIOCON.BO vs VANTABIO.BO Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, VANTABIO.BO has a market cap of 131.6M. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while VANTABIO.BO trades at ₹16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas VANTABIO.BO's P/E ratio is -2.70. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to VANTABIO.BO's ROE of -0.34%. Regarding short-term risk, BIOCON.BO is less volatile compared to VANTABIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check VANTABIO.BO's competition here
BIOCON.BO vs GVBL.BO Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, GVBL.BO has a market cap of 78M. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while GVBL.BO trades at ₹24.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas GVBL.BO's P/E ratio is -232.00. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to GVBL.BO's ROE of +0.03%. Regarding short-term risk, BIOCON.BO is less volatile compared to GVBL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check GVBL.BO's competition here
BIOCON.BO vs SERVOTEACH.BO Comparison April 2026
BIOCON.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOCON.BO stands at 459.2B. In comparison, SERVOTEACH.BO has a market cap of 0. Regarding current trading prices, BIOCON.BO is priced at ₹362.80, while SERVOTEACH.BO trades at ₹20.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOCON.BO currently has a P/E ratio of 74.44, whereas SERVOTEACH.BO's P/E ratio is N/A. In terms of profitability, BIOCON.BO's ROE is +0.02%, compared to SERVOTEACH.BO's ROE of +0.00%. Regarding short-term risk, BIOCON.BO is less volatile compared to SERVOTEACH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOCON.BO.Check SERVOTEACH.BO's competition here